Indegene announces acquisition of BioPharm to Expand AI-Driven Marketing and AdTech for Global Pharma

Indegene announced the strategic acquisition of BioPharm, a Pennsylvania-based specialized marketing services agency and part of Omnicom Health Group. This acquisition by ILSL Inc., a subsidiary of Indegene Limited, strengthens Indegene's commercialization portfolio with AdTech, combining AI and digital advertising, enabling pharma companies to drive more precise, scalable, and measurable outcomes. Further, this solidifies Indegene's position as a true category leader in data-driven Omnichannel and Media Space.

Founded in 2005, BioPharm's clients include 17 of the world's top 25 biopharma organizations. The agency brings deep expertise in omnichannel strategy, end-to-end media journey - spanning strategy, planning and operations, and data-driven campaign execution - blending analytics, automation, and targeted engagement to deliver turnkey precision marketing solutions.

"BioPharm has built an impressive growth flywheel, with advanced tech capabilities, deep therapeutic expertise, and long-standing client relationships. This acquisition reinforces our position as the preferred tech-native, commercialization partner for the life sciences industry, helping clients unlock greater strategic value from their marketing and AdTech investments", said Manish Gupta, Chairman and CEO, Indegene. "I am delighted to welcome Steve and the BioPharm team to the Indegene family, and we look forward to shaping the future of AI-led commercialization together."

"Indegene is a natural home for us, given their client-focused, innovation-first, employee-centric culture - backed by strong technology platforms, data and analytics capabilities, deep medical expertise, marquee client base and a global delivery model. And, we are very excited to join the larger Indegene family at a pivotal time for the industry", said Steve Carickhoff, President, BioPharm. "Their life sciences-contextualized approach to AI will open up new possibilities, helping us deliver deeper value to clients. Together, we will push the boundaries of AI-powered pharma marketing worldwide - delivering more personalized, measurable, and patient-focused outcomes."

Amid changing market dynamics, evolving regulatory complexities, and discerning HCP preferences in an AI-first era, more and more pharma companies are looking to transform their commercialization processes to make bold bets and be truly future-ready. However, traditional healthcare agencies of record are finding it difficult to deliver to pharma's rapidly changing expectations. That's why the industry is turning to specialized solution providers like Indegene, to co-innovate future-ready commercialization models with an AI-first/data-driven approach.

This acquisition by Indegene is especially significant as many pharma companies have the twin agendas of managing mature and growth product portfolios and ramping up capabilities for new launches in an environment where physicians increasingly favor limited engagement models. These imperatives, along with the productivity agenda, are driving the adoption of innovative digital engagement approaches.

The powerful combination of Indegene and BioPharm brings together vast, rich data assets that will drive significantly higher Media ROI and enable more effective Agentic Operations.

Seyfarth Shaw LLP represented Indegene in this transaction.

Shares of Indegene Limited was last trading in BSE at Rs. 561.50 as compared to the previous close of Rs. 572.10. The total number of shares traded during the day was 4755 in over 527 trades.

The stock hit an intraday high of Rs. 570.55 and intraday low of 559.60. The net turnover during the day was Rs. 2680563.00.

Source : Equity Bulls

Keywords

Indegene HealthcareResearch Analytics Technology INE065X01017 Acquisition BioPharm